The consortium aims to develop the HybridHeart, which can completely replace a patient’s heart in a procedure similar to a heart transplant, to provide a cure for heart failure patients. Affecting approximately 23 million people worldwide, heart failure is amongst the most debilitating cardiovascular problems.
Currently, patients with end-stage heart failure will either receive a heart transplant, if available, or a long-term mechanical circulatory support, which causes severe complications.
To achieve the ambitious goal of providing a permanent cure for heart failure patients, the consortium will, in parallel, develop the components of the HybridHeart, i.e.,: 1) a soft elastomeric robotics shell containing actuators and sensors, 2) scaffolds for in situ TE of inner lining, valves and vessels, and 3)a wireless energy transfer system. These components together will form the full HybridHeart, which will be soft, adaptable, wireless and fully bio- and hemocompatible. Both functionality as well as biocompatibility of the HybridHeart will be shown in a Proof-of-Principle study in the chronic sheep model at the end of the project.
The HybridHeart project will be carried out by an interdisciplinary group of (academic) researchers and high-tech SMEs, with experience in cardiac surgery, TE, soft robotics and engineering. The technology underlying the HybridHeart will be applicable to a range of soft robotics-based artificial organs, including the bowel, lung, or muscle structures (limbs).